A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Incyte Corporation
- Study ID
- NCT06212999
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
- Hidradenitis Suppurativa (HS)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Povorcitinib — DRUGOral; Tablet
Study Details
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Key Dates
- Start date
- Jan 30, 2024
- Status verified
- Mar 2026
- Primary completion
- Dec 26, 2026
- Completion
- Dec 26, 2026
Study Design
- Enrollment
- 617 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort APovorcitinib at the protocol-defined dose strength based on cohort assignment.
- Experimental: Cohort BPovorcitinib at the protocol-defined dose strength based on cohort assignment.
- Experimental: Cohort CPovorcitinib at the protocol-defined dose strength based on cohort assignment.
Primary Outcome Measure
Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: up to approximately 56 weeks ]
Locations (61)
Find similar trials in Phoenix, AZ
Related Studies
- Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%EARLY_PHASE1 · Recruiting · Virginia Clinical Research, Inc. · Norfolk, Virginia
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefensePHASE2 · Recruiting · Zura Bio Inc · Phoenix, Arizona
- A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) TherapeuticRecruiting · Sonoma Biotherapeutics, Inc. · San Francisco, California